{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"71","upperLimit":"96","value":"88"},{"groupId":"OG001","lowerLimit":"61","upperLimit":"95","value":"83"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"description":"Response includes both complete and partial responses. Per protocol, complete Response is defined as the complete disappearance of all clinical evidence of disease by physical examination, by imaging studies, by bone marrow biopsy (where indicated), by CNS evaluation (where indicated) and by biopsy where there is a residual abnormality on an imaging study. Bone marrow must contain \\<5% blasts. CSF WBC must be \\<5/μL with no blasts or lymphomatous cells present. Partial response is defined as: at least a 50% reduction in the size of all measurable tumor areas. Each site is to be defined by the product of the maximum length, width and depth (3 dimensions). No lesion may progress. No new lesion may appear. Bone marrow must contain \\<5% blasts. CSF WBC must be \\<5/μL with no blasts or lymphomatous cells present..","dispersionType":"95% Confidence Interval","groups":[{"description":"Therapies given IV, IT, orally, or SC. Please see treatment outline. See Detailed Description.","id":"OG000","title":"Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)"},{"description":"Therapies given IV, IT, orally, or subcutaneously (same as FAB B with the addition of etoposide and high-dose methotrexate). See Detailed Description.","id":"OG001","title":"Group C (Chemotherapy, Monoclonal Antibody Therapy)"}],"paramType":"NUMBER","populationDescription":"Population analyzed includes eligible patients considered evaluable for response (with measurable disease at on study and adequate assessment of response).","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants analyzed"}